Immunology and Microbiology
COVID-19
100%
Seroconversion
100%
Vaccine Efficacy
80%
Rheumatic Disease
72%
B Cell
66%
Severe Acute Respiratory Syndrome Coronavirus 2
57%
Vaccination Policy
46%
Rituximab
42%
Monospecific Antibody
40%
Inflammatory Arthritis
38%
Systemic Lupus Erythematosus
38%
Antibody Response
34%
T Cell
25%
Booster Dose
19%
Immunoglobulin M
16%
Neutralizing Antibody
16%
CD19
13%
Cell Level
13%
Spike
13%
Immunoglobulin A
8%
CD4
8%
Cytotoxic T-Cell
8%
Medicine and Dentistry
Seroconversion
66%
Rheumatic Disease
42%
Rheumatoid Arthritis
41%
Systemic Lupus Erythematosus
41%
COVID-19
39%
Severe Acute Respiratory Syndrome Coronavirus 2
37%
Revaccination
33%
COVID-19 Vaccine
33%
Blood Donor
31%
Rituximab
16%
Patient Health Questionnaire 9
16%
RNA
16%
B Cell
12%
Antibody Response
9%
T-Cell Response
9%
Symptom
8%
Methotrexate
8%
Prednisone
8%
Immunoglobulin M
6%
Neutralizing Antibody
6%
Biochemistry, Genetics and Molecular Biology
Seroconversion
66%
SARS Coronavirus
58%
Monospecific Antibody
41%
T Cell
33%
Messenger RNA
33%
Coronavirinae
33%
B Cell
33%
Antibody Response
25%
Neutralizing Antibody
16%
Immunoglobulin M
16%
Rituximab
16%
Spike
8%
Prednisone
8%
CD4
8%
CD8
8%
Immunoglobulin A
8%
Comorbidity
8%
Cell Level
8%
Methotrexate
8%
CD19
8%